ATE355844T1 - Zusammensetzung zur männlichen kontrazeption, norethisteron und testosteron undecanoat enthaltend - Google Patents

Zusammensetzung zur männlichen kontrazeption, norethisteron und testosteron undecanoat enthaltend

Info

Publication number
ATE355844T1
ATE355844T1 AT01902590T AT01902590T ATE355844T1 AT E355844 T1 ATE355844 T1 AT E355844T1 AT 01902590 T AT01902590 T AT 01902590T AT 01902590 T AT01902590 T AT 01902590T AT E355844 T1 ATE355844 T1 AT E355844T1
Authority
AT
Austria
Prior art keywords
norethisterone
testosterone
composition
male contraception
testosterone undecanoate
Prior art date
Application number
AT01902590T
Other languages
German (de)
English (en)
Inventor
Eberhard Nieschlag
Axel Kamischke
Michael Oettel
Alexander Ruebig
Ekkerhard Schillinger
Ursula-Friederike Habenicht
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of ATE355844T1 publication Critical patent/ATE355844T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT01902590T 2000-02-15 2001-02-15 Zusammensetzung zur männlichen kontrazeption, norethisteron und testosteron undecanoat enthaltend ATE355844T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50372900A 2000-02-15 2000-02-15
EP00200493 2000-02-15

Publications (1)

Publication Number Publication Date
ATE355844T1 true ATE355844T1 (de) 2007-03-15

Family

ID=26071832

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01902590T ATE355844T1 (de) 2000-02-15 2001-02-15 Zusammensetzung zur männlichen kontrazeption, norethisteron und testosteron undecanoat enthaltend
AT06075322T ATE474580T1 (de) 2000-02-15 2001-02-15 Zusammensetzung zur männlichen kontrazeption, norethisteron enthaltend

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06075322T ATE474580T1 (de) 2000-02-15 2001-02-15 Zusammensetzung zur männlichen kontrazeption, norethisteron enthaltend

Country Status (26)

Country Link
EP (2) EP1267885B8 (enExample)
JP (1) JP2003522795A (enExample)
KR (1) KR20020086905A (enExample)
CN (1) CN1423560A (enExample)
AT (2) ATE355844T1 (enExample)
AU (1) AU2001230447A1 (enExample)
BG (1) BG107066A (enExample)
BR (1) BR0108411A (enExample)
CA (1) CA2398063A1 (enExample)
CY (1) CY1106639T1 (enExample)
CZ (1) CZ20022691A3 (enExample)
DE (2) DE60127103T2 (enExample)
DK (1) DK1267885T3 (enExample)
EE (1) EE200200454A (enExample)
ES (1) ES2282230T3 (enExample)
HK (1) HK1049442B (enExample)
HU (1) HUP0300128A3 (enExample)
IL (1) IL151219A0 (enExample)
MX (1) MXPA02007675A (enExample)
NO (1) NO20023607L (enExample)
PL (1) PL357185A1 (enExample)
PT (1) PT1267885E (enExample)
RU (1) RU2002124602A (enExample)
SI (1) SI1267885T1 (enExample)
SK (1) SK11602002A3 (enExample)
WO (1) WO2001060376A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234525A1 (de) * 2002-07-25 2004-02-05 Schering Ag Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
NZ549529A (en) 2002-07-24 2008-04-30 Schering Aktiengellschaft Microbiological processes for the production of 7alpha-substituted 11alpha-hydroxy steroids
WO2004011008A1 (de) * 2002-07-25 2004-02-05 Schering Aktiengesellschaft ZUSAMMENSETZUNG, ENTHALTEND EIN ANDROGENES 11β-HALOGENSTEROID UND EIN GESTAGEN SOWIE MÄNNLICHES KONTRAZEPTIVUM AUF BASIS DIESER ZUSAMMENSETZUNG
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
CN101352443B (zh) * 2007-07-23 2011-01-12 中国科学院动物研究所 哺乳动物雄性不育剂
KR102496504B1 (ko) 2018-03-23 2023-02-06 라보라뚜아르 마조르 남성 피임을 위한 비호르몬 조성물 및 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714420A1 (de) * 1976-06-01 1977-12-08 Int Pregnancy Advisory Service Antikonzeptionsmittel zur verabreichung an mann und frau in einer gemeinsamen verabreichungspackung
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
DE19650352A1 (de) * 1996-12-04 1998-07-30 Jenapharm Gmbh Oral wirksames Kombinationspräparat zur Kontrazeption für den Mann

Also Published As

Publication number Publication date
CA2398063A1 (en) 2001-08-23
NO20023607L (no) 2002-10-15
JP2003522795A (ja) 2003-07-29
HK1049442B (en) 2007-06-15
EP1666044A1 (en) 2006-06-07
CZ20022691A3 (cs) 2003-01-15
AU2001230447A1 (en) 2001-08-27
MXPA02007675A (es) 2004-02-26
ATE474580T1 (de) 2010-08-15
EP1267885B8 (en) 2007-06-20
SI1267885T1 (sl) 2007-08-31
SK11602002A3 (sk) 2003-03-04
HUP0300128A3 (en) 2004-03-29
HK1049442A1 (en) 2003-05-16
WO2001060376A1 (en) 2001-08-23
DE60127103T2 (de) 2007-11-22
EE200200454A (et) 2003-12-15
DE60127103D1 (de) 2007-04-19
PT1267885E (pt) 2007-05-31
DE60142647D1 (de) 2010-09-02
EP1267885B1 (en) 2007-03-07
BG107066A (en) 2003-05-30
DK1267885T3 (da) 2007-07-09
PL357185A1 (en) 2004-07-26
CN1423560A (zh) 2003-06-11
IL151219A0 (en) 2003-04-10
EP1666044B1 (en) 2010-07-21
KR20020086905A (ko) 2002-11-20
BR0108411A (pt) 2003-03-11
CY1106639T1 (el) 2012-01-25
NO20023607D0 (no) 2002-07-30
HUP0300128A2 (en) 2003-05-28
ES2282230T3 (es) 2007-10-16
EP1267885A1 (en) 2003-01-02
RU2002124602A (ru) 2004-03-10

Similar Documents

Publication Publication Date Title
CY1106639T1 (el) Τυποποιηση αντισυλληπτικου για ανδρες που περιλαμβανει νορεθιστερονη
RU99118582A (ru) Композиция для чрескожного введения стероидных лекарственных средств
HK1056181A1 (zh) 作為抗炎劑的17β-硫代羧酸酯17α-芳基羰氧基氧雄甾烷衍生物
NO20032805D0 (no) Preparater av östrogensyklodekstrinkomplekser
FI884378A0 (fi) Farmaceutiskt preparat och foerfarande foer framstaellning av detsamma.
CA2084891A1 (en) Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders
KR960704553A (ko) 적어도 하나의 프로게스토겐과 적어도 하나의 에스트로겐을 함유하는 대용요법용 제제(preparation for substitution therapy containing at least one progestogen and at least one estrogen)
AR073972A2 (es) Composiciones farmaceuticas para el tratamiento de carencias estrogenicas en la menopausia y para la prevencion de la osteoporosis en mujeres menopausicas
JP4716726B2 (ja) 新しいエトノゲストレルエステル
DE59510887D1 (de) Feste arzneiformen, enthaltend clathrate vom steroidalen sexualhormon ethinylestradiol
KR970010784A (ko) 11-(치환된 페닐)-에스트라-4,9-디엔 유도체
BR0113376A (pt) Uso de um éster de testosterona, método de tratamento de distúrbios de insuficiência de androgênio, e, sistema de liberação de droga para contracepção masculina
WO2004006936A8 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
ATE225800T1 (de) Nichtestrogene derivate des estradiols mit antioxidativer aktivität
WO2001040255A3 (en) 14,15-beta-methylene substituted androgens
AU1967300A (en) Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
RU2002113652A (ru) Гормональная композиция на основе гестагена и эстрогена и ее применение
AR027526A1 (es) Formulacion anticonceptiva masculina que comprende noretisterona
JP2003522795A5 (enExample)
JP2005532336A (ja) 新規なエトノゲストレルエステルの使用
IE34308B1 (en) 11beta,13beta dialkylgona-1,3,5(10)-trien-3-ol 3-cycloalkyl ethers
WO2003032924A3 (en) Novel tibolone formulations
PL360669A1 (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
JPS5936611A (ja) 粘着性貼付製剤
TW228472B (en) Estrogen nucleus derivatives for use in the inhibition of sex steroid activity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1267885

Country of ref document: EP